论文信息 - Clazosentan for patients with subarachnoid haemorrhage: lessons learned – Authors' reply - 字舞流文

Clazosentan for patients with subarachnoid haemorrhage: lessons learned – Authors' reply

S. Mayer | R. Higashida | E. Keller | A. Molyneux | R. Macdonald | A. Raabe | P. Vajkoczy | I. Wanke | S. Roux | N. Kassell | D. Bach | A. Marr | A. Frey

[1] S. Mayer,et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) , 2011, The Lancet Neurology.

[2] T. Gin,et al. Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH): A Randomized, Double-Blinded, Placebo-Controlled, Multicenter Phase III Trial , 2010, Stroke.

[3] S. Mayer,et al. Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1): Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial , 2008, Stroke.

[4] B. Meyer,et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. , 2005, Journal of neurosurgery.

[5] R. Macdonald,et al. Metaanalysis of Tirilazad Mesylate in Patients with Aneurysmal Subarachnoid Hemorrhage , 2009, Neurocritical care.